FdaApplication
NDA 022496
Identifiers
- fda_app_no: NDA022496
Properties
| Property | Value |
|---|---|
| applicant_name | PACIRA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2011-10-28 |
Revenue by product
EXPAREL
| Period | Revenue |
|---|---|
| Q2 2026 | $147.8M |
| Q1 2026 | $143.3M |
| Q4 2025 | $155.8M |
| Q3 2025 | $139.9M |
| Q2 2025 | $142.9M |
| Q1 2025 | $136.5M |
| Q4 2024 | $147.7M |
| Q3 2024 | $132.0M |
| Q2 2024 | $136.9M |
| Q1 2024 | $132.4M |
| Q4 2023 | $143.9M |
| Q3 2023 | $257.3M |
| Q2 2023 | $135.1M |
| Q1 2023 | $130.4M |
| Q3 2022 | $132.6M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EXPAREL | BUPIVACAINE | 266MG/20ML (13.3MG/ML) | INJECTABLE, LIPOSOMAL;INJECTION |
| EXPAREL | BUPIVACAINE | 133MG/10ML (13.3MG/ML) | INJECTABLE, LIPOSOMAL;INJECTION |
2 products